Literature DB >> 25671954

Common risk factors for the development of anti tuberculosis treatment induced hepatotoxicity.

Munir Ahmad Abbasi, Naseer Ahmed, Amir Suleman, Haidar Zaman, Sumbal Tariq, Syed Abbas Anwar, Nisar Khan.   

Abstract

BACKGROUND: Tuberculosis is a global pandemic which affects millions of people every year. The treatment of tuberculosis consists of simultaneous use of a number of drugs for a prolonged period of time, therefore anti-tuberculosis treatment induced toxicity is a real problem. Many risk factors which make a tuberculosis patient prone to the development of hepatotoxicity associated with the anti-tuberculosis treatment have been identified. The aim of this study was to determine common risk factors responsible for precipitation of hepatotoxicity following treatment with anti-tuberculosis drugs.
METHODS: This cross-sectional study was conducted in the Department of Pulmonary Medicine, Ayub Teaching Hospital, Abbottabad from 20th April 2013 to 19th March 2014. Patients -' , who were newly diagnosed cases of tuberculosis in whom treatment of tuberculosis with first line anti-tuberculosis drugs was initiated and were 20 years or older, were included. The precipitation of drug induced hepatotoxicity was diagnosed with detailed history taking and physical examination followed by laboratory investigations, i.e., Liver Function tests (LFT).
RESULTS: Of the total 179 patients included in this study, 100 (55.8 %) were males and 79 (44.2 %) were females. Out of them 23 (12.85%) developed hepatotoxicity. Drug induced hepatotoxicity was observed in the older patients. No relationship was found with the sex, body mass index (BMI), and pre-existing liver disease.
CONCLUSION: The study showed that the risk of development of drug-induced hepatotoxicity following treatment with first line anti-tuberculosis treatment increased with the age of the patient.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25671954

Source DB:  PubMed          Journal:  J Ayub Med Coll Abbottabad        ISSN: 1025-9589


  5 in total

1.  Successful desensitization therapy involving fluoroquinolone for the treatment of a solitary tuberculoma: A case report and literature review.

Authors:  Hidehiro Watanabe; Tomonori Uruma; Ikuo Seita; Yushi Chikasawa; Ryota Kikuchi; Masayuki Itoh; Kazutetsu Aoshiba; Hiroyuki Nakamura; Tsuyoshi Oishi
Journal:  Mol Clin Oncol       Date:  2016-04-28

2.  Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury.

Authors:  Yifan Bao; Xiaochao Ma; Theodore P Rasmussen; Xiao-Bo Zhong
Journal:  Curr Pharmacol Rep       Date:  2018-03-15

3.  Adverse Events in Treating Smear-Positive Tuberculosis Patients in China.

Authors:  Tao Zhang; Jian Du; Xiaoyan Yin; Fuzhong Xue; Yanxun Liu; Runzi Li; Cheng Luo; Liang Li; Xiujun Li
Journal:  Int J Environ Res Public Health       Date:  2015-12-29       Impact factor: 3.390

4.  Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia.

Authors:  Yalew Molla; Muluken Wubetu; Bekalu Dessie
Journal:  Hepat Med       Date:  2021-01-28

5.  Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North Ethiopia: A cross-sectional study.

Authors:  Liwam Kidane Gezahegn; Ermias Argaw; Belete Assefa; Azeb Geberesilassie; Mengistu Hagazi
Journal:  PLoS One       Date:  2020-11-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.